We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
-2.52%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$439M
AUM Growth
+$75.3M
Cap. Flow
-$56.5M
Cap. Flow %
-12.86%
Top 10 Hldgs %
60.79%
Holding
73
New
15
Increased
16
Reduced
20
Closed
21

Top Buys

Rank Stock Value
1
HUM icon
Humana
HUM
+$12M
2
JNJ icon
Johnson & Johnson
JNJ
+$11.1M
3
SIBN icon
SI-BONE Inc
SIBN
+$10.9M
4
ABBV icon
AbbVie
ABBV
+$10.8M
5
BMY icon
Bristol-Myers Squibb
BMY
+$7.29M

Top Sells

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$15M
2
LH icon
Labcorp
LH
+$12.9M
3
ICLR icon
Icon
ICLR
+$7.95M
4
HAE icon
Haemonetics
HAE
+$7.86M
5
CI icon
Cigna
CI
+$7.76M

Sector Composition

Rank Sector Weight
1 Healthcare 60.22%
2 Industrials 1.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RNAC icon
26
Cartesian Therapeutics
RNAC
$243M
$4.25M 0.97%
34,050
+3,152
+10% +$381K
MTEM
27
DELISTED
Molecular Templates, Inc.
MTEM
$4.12M 0.94%
40,909
-8,959
-18% -$924K
ALBO
28
DELISTED
Albireo Pharma Inc
ALBO
$3.66M 0.83%
117,328
+13,816
+13% +$427K
PHAS
29
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$3.52M 0.8%
1,132,523
-997,186
-47% -$3.33M
XRAY icon
30
Dentsply Sirona
XRAY
$2.75B
$3.52M 0.8%
60,620
-43,240
-42% -$2.67M
RVTY icon
31
Revvity
RVTY
$12.8B
$3.34M 0.76%
+19,264
New +$3.39M
IOVA icon
32
Iovance Biotherapeutics
IOVA
$1.98B
$3.23M 0.74%
131,098
-29,264
-18% -$690K
PRAX icon
33
Praxis Precision Medicines
PRAX
$8.86B
$2.84M 0.65%
10,240
-3,064
-23% -$831K
BDX icon
34
Becton Dickinson
BDX
$46.6B
$2.72M 0.62%
+11,354
New +$2.78M
SNY icon
35
Sanofi
SNY
$102B
$2.64M 0.6%
+54,821
New +$2.79M
COR icon
36
Cencora
COR
$61.6B
$2.56M 0.58%
21,430
-20,299
-49% -$2.44M
RGLS
37
DELISTED
Regulus Therapeutics
RGLS
$2.45M 0.56%
354,721
+93,954
+36% +$688K
BLU
38
DELISTED
BELLUS Health Inc.
BLU
$2.39M 0.55%
389,833
-16,704
-4% -$63.3K
DRIO icon
39
DarioHealth
DRIO
$69.7M
$2.05M 0.47%
7,500
-5,439
-42% -$1.57M
MREO
40
Mereo BioPharma
MREO
$48.7M
$1.81M 0.41%
746,514
-10,401
-1% -$27.5K
AXSM icon
41
Axsome Therapeutics
AXSM
$10.9B
$1.72M 0.39%
+52,048
New +$2.03M
IMUX icon
42
Immunic
IMUX
$191M
$1.64M 0.37%
18,545
+830
+5% +$81.7K
MRVI icon
43
Maravai LifeSciences
MRVI
$943M
$1.46M 0.33%
+29,838
New +$1.46M
ACRS icon
44
Aclaris Therapeutics
ACRS
$877M
$1.21M 0.28%
67,300
-52,078
-44% -$835K
KRYS icon
45
Krystal Biotech
KRYS
$9.59B
$1.2M 0.27%
+22,938
New +$1.36M
BOLT icon
46
Bolt Biotherapeutics
BOLT
$7.59M
$1.14M 0.26%
+4,502
New +$1.27M
KLRS
47
Kalaris Therapeutics
KLRS
$99.2M
$1.11M 0.25%
+1,932
New +$895K
XENE icon
48
Xenon Pharmaceuticals
XENE
$6.2B
$959K 0.22%
+62,743
New +$1.09M
PDCO
49
DELISTED
Patterson Companies, Inc.
PDCO
$808K 0.18%
+26,799
New +$814K
CYAD
50
DELISTED
Celyad Oncology SA American Depositary Shares
CYAD
$596K 0.14%
145,380
-15,311
-10% -$67K
1
2
3

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Endurant Capital Management held 73 positions worth $439M, up 21% from $364M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Endurant Capital Management withdrew a net $56.5M in Q3 2021, closing 21 positions and reducing 20 holdings. Its most notable exit was Thermo Fisher Scientific, an estimated $15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 80% a quarter earlier, followed by Industrials.

Against the trend, Endurant Capital Management opened a new position in AptarGroup worth $6.11M.

  • Endurant Capital Management's largest Q3 2021 buy was AptarGroup: 51,191 shares worth $6.11M.
  • Endurant Capital Management added most to Humana in Q3 2021, an estimated $12M increase.
  • Endurant Capital Management's biggest Q3 2021 reduction was Labcorp, cutting an estimated $12.9M.
  • Endurant Capital Management fully exited Thermo Fisher Scientific in Q3 2021, selling an estimated $15M.
  • Endurant Capital Management's ten largest holdings make up 61% of its $439M portfolio in Q3 2021.
  • Endurant Capital Management opened 15 new positions and closed 21 in Q3 2021.
  • Endurant Capital Management's portfolio value rose 21% quarter-over-quarter to $439M.

Based on Endurant Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.